Introduction:Obesity may be associated with more severe and disabling low backache (LBA) due to alteration in biomechanics, but there are no such studies from developing countries.Aims:We report the frequency of metabolic syndrome (MS) in chronic LBA (CLBA) and its association with severity and disability of CLBA.Subjects and Methods:Consecutive patients with CLBA attending to the neurology service from October 2015 to February 2016 were included in the study. Clinical and demographic parameters were recorded. Routine biochemical test was done. The severity of pain was assessed by a 0–10 Numeric Rating Scale (NRS) and disability by Oswestry Disability Index (ODI) version 2. Comparison of variables was done by Chi-square or independent t-test and correlation by Karl Pearson or Spearman's rank correlation test.Results:Seventy-none (39.3%) patients had MS as per the International Diabetic Federation (IDF) criteria and 68 (33.8%) as per the National Cholesterol Education Program Adult Treatment Panel III criteria. Abdominal obesity was the most common (171 [85.1%]) feature of MS. The patients with MS had longer duration of sitting work and did less frequently exercise. The NRS score (6.95 ± 1.06 vs. 6.65 ± 0.95; P = 0.04) and ODI score (54.91 ± 8.42 vs. 51.89 ± 8.54; P = 0.01) were higher in CLBA patients with MS compared to those without MS.Conclusion:About 40% patients with CLBA have metabolic syndrome, and they have more severe pain and disability.
Acute stroke is a medical emergency which can cause permanent neurological damage, complications and even may leads to death. Results of stroke vary widely depending on the size and location of the lesions. It is a heterogeneous condition with respect to prognosis. It is not possible to predict exact outcome of stroke with accuracy. The chances of survival in stroke depend on a great variety of variables. Globally, approximately 15 million new acute stroke events occur every year and approximately 55 million people had stroke at some time in the past. Two thirds of these individuals live in lowand middle-income countries such as India. By 2050, it is anticipated that 80% of stroke events will occur in people living in these regions. 1 A recent Indian study have shown different prevalence rates in rural and urban areas (rural areas 84-262/100,000; urban areas 334-424/100,000) with incidence rate of 119-145/100,000 and 30 day case fatality was found to be 41.08%. 2 According to Indian collaborative acute stroke study (2002)(2003)(2004) with 2162 cases, stroke incidence higher in age group of 41-70
Aim – To assess the prognostic value of Platelet lymphocyte ratio (PLR) in acute hemorrhagic stroke as
compared to acute ischemic stroke Material And Methods – A Prospective observational study was
conducted at MLN Medical College, Prayagraj. A total of 100 adult patients, 50 each of ischemic and hemorrhagic stroke (as per
CT/MRI diagnosis) were enrolled in the study, with onset of stroke within 48 hours, after following inclusion and exclusion
criterias. Result – In-hospital mortality was signicantly higher in hemorrhagic (56%) as compared to ischemic stroke (26%)
(p=0.002). Mean platelet lymphocyte ratio was signicantly higher in hemorrhagic (186.76 +-102.4) as compared to ischemic
stroke (128.83 +- 78.3) (p=0.002). In hemorrhagic stroke, higher PLR showed a signicant association with mortality (p<0.05)
Conclusion – PLR was signicantly higher in hemorrhagic stroke as compared to ischemic stroke and correlated with higher
mortality in hemorrhagic stroke. Therefore, PLR showed a possible prognostic value with respect to mortality in hemorrhagic
stroke patients as compared to ischemic stroke.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.